Brought to you by 
Laguna Pharmaceuticals closes $30mm Series B round
17 Feb 2015
Executive Summary
Laguna Pharmaceuticals Inc. (formerly ChanRx) raised $30mm in its Series B financing led by Versant Ventures and Frazier Healthcare, which each add a board member and were joined by other first-time backers BioMed Ventures and returning shareholder Sante Ventures. Laguna will use the money to advance its lead candidate vanoxerine into Phase III for atrial fibrillation and atrial flutter.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Laguna Pharmaceuticals closes $30mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice